miR-200家族作为卵巢癌预后标志物的meta分析  

Prognostic Role of mi R-200 Family in Ovarian Cancer: a Meta-analysis

作　　者：朱晓南[1] 宗利丽[2] 付文博[3] 郝双[1] 管雁丞[4] 张宸铭[5] 

机构地区：[1]南方医科大学珠江医院,广东广州510282 [2]南方医科大学中西医结合医院,广东广州510515 [3]石河子大学第一附属医院,新疆石河子832008 [4]深圳市中医院,广东深圳518033 [5]广州中医药大学,广东广州510405

出　　处：《现代生物医学进展》2015年第2期343-346,共4页Progress in Modern Biomedicine

基　　金：广东省人口和计划生育委员会科研项目(20110272)

摘　　要：目的:系统评价mi R-200家族(mi R-200a、mi R-200b、mi R-200c、mi R-141、mi R-429)的表达与卵巢癌预后之间的关系。方法:仔细检索搜索美国国立图书馆(Pub Med),荷兰医学文摘(EMBASE)以及ISI Web of Science、CNKI、万方等数据库,与mi R-200家族相关的卵巢癌预后的文献。检索日期为数据库的建库时间至2013年9月20日。提取与mi R-200家族相关卵巢癌预后的相应数据,应用Stata11.0软件进行Meta分析。结果:共有7篇研究符合入选标准,累积肿瘤组织577例。Meta分析显示,mi R-200家族低表达组的合并优势比是高表达组的1.347倍(95%CI:1.052,1.725)。mi R-200a、mi R-200c、mi R-141的亚组分析结果分别为1.091(95%CI:0.718,1.659)、1.285(95%CI:0.765,2.161),1.122(95%CI:1.043-1.208)。mi R-200家族、mi R-141与卵巢癌的预后之间的关系有统计学意义(P=0.018,P=0.002)。结论:mi R-200家族在卵巢癌的预后判断中可能起到预后标记物的作用。Objective： To systemically evaluate the relationship between miR-200 family and the prognosis of ovarian cancer. Methods： A computer-based retrieval of PubMed, EMBASE, Web of Science, CNKI and Wanfang Database was performed for correlative literature to aggregate the survival results from their establishment to September 2013. Relevant data were extracted from studies investigating the relationship between miR-200 family expression and survival in ovarian cancer patients. The data were analyzed with meta analysis using Stata vl 1.0 soRware. Results： Seven studies were identified, involving 577 cases with ovarian cancer. Meta-analysis results showed that, the combined hazard ratio （HR） for miR-200 family in ovarian cancer was 1.347 （95%CI： 1.052, 1.725）. Subgroup ofmiR-200a, miR-200c and miR-141 subjects for survival were 1.091 （95%CI：0.718, 1.659）, 1.285 （95%CI：0.765, 2.161 ）, and 1.122 （95% CI： 1.043, 1.208）, respectively. The risk ofmiR-200 family, miR-141 for prognosis in ovarian cancer patients was significant （P = 0.018, P = 0.002））. Conclusions： miR-200 family may act as a prognostic biomarker.

关 键 词：miR-200家族 卵巢癌 预后 肿瘤标记 META分析 

分 类 号：R737.31[医药卫生—肿瘤]